Patients with the rs4149056 TT genotype may have a decreased risk of developing myopathy when treated with pravastatin as compared to patients with the CC or CT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect a patient's risk of experiencing pravastatin-induced myopathy.